Kanglexin protects against cardiac fibrosis and dysfunction in mice by TGF-β1/ERK1/2 noncanonical pathway

• Главные авторы: Xue Liu (Автор), Weina Han (Автор), Na An (Автор), Na Cao (Автор), Tingting Wu (Автор), Shuang Yang (Автор), Lili Ding (Автор), Xiaoli Chen (Автор), Chao Chen (Автор), Aruhan (Автор), Yannan Zhang (Автор), Kexin Wang (Автор), Lianhuan Suo (Автор), Jian Huang (Автор), Jinhui Wang (Автор), Xin Zhao (Автор), Jiuxin Zhu (Автор), Yan Zhang (Автор), Baofeng Yang (Автор)
• Формат: ‌
• Опубликовано: Frontiers Media S.A., 2021-01-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Cardiac fibrosis is a common pathological manifestation accompanied by various heart diseases, and antifibrotic therapy is an effective strategy to prevent diverse pathological processes of the cardiovascular system. We currently report the pharmacological evaluation of a novel anthraquinone compoun...